Form 4: Beta Bionics Chief Medical Officer Sells Shares to Cover Tax Obligations

Beta Bionics, Inc.'s Chief Medical Officer, Steven Jon Russell, sold 1,039 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc. (BBNX), reported the sale of common stock.
• The transactions occurred on June 2, 2025.
• A total of 1,039 shares were sold across three separate transactions.
• The sales were executed at weighted average prices of $17.028, $18.1489, and $18.691.
• The purpose of the sales was to cover tax withholding obligations arising from the vesting of restricted stock units.
• Following these transactions, Mr. Russell directly beneficially owns 72,032 shares of common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary sale.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale for tax purposes, which is common for executives receiving equity compensation. It does not reflect a positive or negative sentiment about the company's future prospects.

Positives

• The sale was non-discretionary, specifically to cover tax withholding obligations, which is a routine event for executives receiving equity compensation.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on new material non-public information.

Negatives

• A reduction in direct beneficial ownership by a key officer, although for a specific tax purpose, slightly decreases management's direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing. It does not provide specific insights into broader industry trends for medical devices or biotechnology, other than reflecting standard executive compensation practices involving equity.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but for a routine tax purpose, so minimal impact on investor confidence.
• Employees: No direct impact on employees beyond the reporting officer.

Key Dates

Recommendation

Keywords

Beta Bionics, BBNX, Form 4, Insider Trading, Stock Sale, Chief Medical Officer, Steven Jon Russell, Tax Withholding, Restricted Stock Units, Equity Compensation, Rule 10b5-1